Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-1


Brief Information

Name:Cluster of differentiation 80
Target Synonym:Activation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimulatory Factor CD80,CD80 Antigen,B7-1,B7.1,B7-1 Antigen,B7,CD80,CD28LG
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

B71-H52A4-Cell-based assay
 B7-1 FACS

Flow Cytometry assay shows that Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 1 μg/mL (Routinely tested).

B71-H52A4-Cell-based assay
 B7-1 FACS

FACS analysis shows that the binding of Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-1 is 1 μg /mL. The IC50 is 5.5 μg/mL (Routinely tested).

 B7-1 SPR

Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Mouse B7-1, Fc Tag (Cat. No. CD0-M5259) captured on CM5 chip via anti-human IgG Fc antibody can bind Mouse CD28, His Tag (Cat. No. CD8-M52H6) with an affinity constant of 49.6 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Customer Reviews

Synonym Name



B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg Approved Bristol-Myers Squibb Company Nulojix EU Rejection of renal transplantation Bristol-Myers Squibb Pharma Eeig 2011-06-15 Rejection of renal transplantation; Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection of organ transplantation; Delayed Graft Function; Rejection in heart transplantation; Kidney Failure, Chronic Details
Abatacept ONO-4164; BMS-188667; BMS-188667SC; ONO-4164SC Approved Bristol-Myers Squibb Company Orencia United States Graft vs Host Disease Bristol Myers Squibb Srlcompany 2005-12-23 Arthritis, Psoriatic; Arthritis; Arthralgia; Common Variable Immunodeficiency; Cardiovascular Diseases; Sjogren-Larsson Syndrome; Urticaria; Asthma; Colitis, Ulcerative; Nephrotic Syndrome; Lupus Erythematosus, Systemic; Takayasu Arteritis; Psoriasis; Anemia, Aplastic; Glomerulosclerosis, Focal Segmental; Mucopolysaccharidosis I; Polymyalgia Rheumatica; Multiple Sclerosis; Leukocyte-Adhesion Deficiency Syndrome; Uveitis; Granulomatous Disease, Chronic; Lymphohistiocytosis, Hemophagocytic; Scleroderma, Diffuse; Inflammation; Myocarditis; Eye Diseases; Muscular Diseases; Crohn Disease; Behcet Syndrome; Kostmann Syndrome; Anemia, Sickle Cell; Thrombasthenia; Vitiligo; Spondylitis, Ankylosing; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Granulomatosis with Polyangiitis; Wiskott-Aldrich Syndrome; Polymyositis; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Hematologic Diseases; Alopecia Areata; Giant Cell Arteritis; Myositis; Dermatomyositis; Immunoglobulin G Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Membrane bound ligand T-SIGn virus NG-348 Phase 1 Clinical Psioxus Therapeutics Ltd Neoplasms Details
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA University Hospital Basel Details
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 Kahr Medical Details
Belatacept biosimilar (Alphamab) KN-019 Phase 2 Clinical Rejection of renal transplantation; Arthritis, Rheumatoid Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Co Ltd Carcinoma, Non-Small-Cell Lung Details
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) Phase 1 Clinical Beijing Vdjbio Co Ltd Arthritis, Rheumatoid Details
ORCA-010 ORCA-010 Phase 2 Clinical Orca Therapeutics Bv Prostatic Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message